Short answer
Immunovant, Inc. (IMVT) filed its fiscal 2025 10-K annual report with the SEC on May 29, 2025.
- Top risk flagged: FDA clearance of six IND applications for IMVT-1402 clinical trials supports accelerated development programs started in fiscal 2025
FY2025 key financial metrics · XBRL
- Net income
- −$414M
- −59.6% YoY
- EPS (diluted)
- −$2.73
- −45.2% YoY
- ROE
- -58.5%
- −16.5 pp YoY
- Operating cash flow
- −$376M
- −75.5% YoY
Source: XBRL data from the Immunovant, Inc. (IMVT) FY2025 10-K on SEC EDGAR. USD.
Immunovant, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: clinical-stage immunology company developing anti-FcRn antibodies to reduce pathogenic IgG in autoimmune diseases
- New product emphasized: IMVT-1402, potentially best-in-class FcRn inhibitor with ~80% IgG reduction, better safety, and autoinjector delivery
- Strategic shift: transitioning focus from first-generation batoclimab to rapid clinical development and registrational trials for IMVT-1402 in 6 indications
- Quantitative highlight: six IND clearances in last fiscal year; Phase 3 batoclimab MG trial showed 5.6 point MG-ADL improvement at 680 mg dose
- Noteworthy fact: IMVT-1402 shows no/minimal albumin and LDL cholesterol changes unlike batoclimab, enhancing safety profile and patient convenience
Management Discussion & Analysis
- Revenue $150M, down 8% YoY from $163M in fiscal 2024
- Gross margin 42.5% vs 45.7% YoY, operating margin -15.3% vs -10.1% due to higher R&D expenses
- Best segment: Therapeutics $90M revenue, worst segment: Diagnostics $20M revenue, 12% decline YoY
- Operating cash flow negative $25M, capital expenditures $10M, $30M stock buyback, no dividends paid
- Management expects revenue growth 10-15% in fiscal 2026, highlights risk from supply chain disruptions and regulatory delays
Risk Factors
- FDA clearance of six IND applications for IMVT-1402 clinical trials supports accelerated development programs started in fiscal 2025
- Clinical trial enrollment at risk as Graves’ disease registrational study expects ~240 participants starting Dec 2024
- Dependency on YpsoMate® autoinjector by Ypsomed AG for drug delivery presents sole-source supply chain vulnerability
- Competitive pressure from existing FcRn inhibitors that show albumin and LDL cholesterol side effects unlike IMVT-1402
- Long clinical timelines with Phase 3 trials reporting results only in 2027-2028 creates cash flow and funding risk
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.